BBNX · Beta Bionics, Inc.
$15.81
-0.18 (-1.13%)
At close · Jul 28
Market Cap
$704.07M
Shares
44.56M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$15.99
Open$16.30
Day$15.50–16.32
52W$8.80–32.71
Avg vol 30d1.1M
Short int6.6M · 14.8% float · 7.0d
Short vol33%
Last earningsApr 21, 2026
DataJan 2025–Jul 2026
Filing10-Q · Apr 21
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Apr 21, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Sell
Momentum
Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−10%
below
Price vs 50-day avg
+12%
above
RSI (14)
50
neutral
MACD trend
Negative
52-week position
30%
mid-range
Momentum
relative strength
1-month return
+1%
trailing
6-month return
+16%
trailing
YTD return
−48%
this year
Relative strength
+9%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $14 › 200d $18 — 200d above 50d
Institutional flow
Distributing
24 of 131 funds reported for Jun 30 · net -355.4K sh shares · +9 new
Insider flow
Distributing
Net -$556.2K over 90 days · 100% sells
Short interest
Falling
14.83% of float · ▼ -3.1% MoM · 7.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
131 holders — mid 1-yr range
Squeeze score
82
high risk · 0–100
Fundamentals
Revenue growth
+54%
Y/Y
Gross margin
55%
expanding
EPS growth
+79%
Y/Y
Free cash flow
$-56.2M
Balance sheet
$31.6M
net cash
Quant / Vol
risk profile
Volatility
83%
annualized · 1-yr
Max drawdown
−72%
past year
ATR
7.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Apr 21, 2026
Total revenue
· full year 2026
Maintained
$131M – $136M
prior FY $100.25M
midpoint +33.2% Y/Y
New patient starts reimbursed through the PBP channel
· full year 2026
Initiated
37% – 39%
Gross margin
· full year 2026
Maintained
57.5% – 59.5%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−10%
Bearish
Price vs 50-day avg
+12%
Bullish
RSI (14)
50
Neutral
MACD trend
Negative
Bearish
52-week position
30%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $14 › 200d $18 — 200d above 50d
Institutional flow
Distributing
24 of 131 funds reported for Jun 30 · net -355.4K sh shares · +9 new
Insider flow
Distributing
Net -$556.2K over 90 days · 100% sells
Short interest
Falling
14.83% of float · ▼ -3.1% MoM · 7.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
131 holders — mid 1-yr range
Price context
position in its 52-week range
52-wk low $9
Now $16 · 30%
52-wk high $33
vs 200-day avg -10%
vs 50-day avg +12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| New patient starts from multiple daily injections (MDI) | 70% | first quarter of 2026 | — |
| Installed customer base | 35,011 | Q4 FY2025 | — |
| New patient starts | 19,713 | FY2025 | — |
| New patient starts from MDI as a percentage of total new patient starts | 70% | FY2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BBNX
this stock
Beta Bionics, Inc.
|
$704.07M | -47.5% | +53.9% | — | 14.8% |
|
ABT
Abbott Laboratories
|
$186.84B | -13.9% | +5.7% | 30.1 | 1.4% |
|
SYK
Stryker Corp
|
$132.87B | -1.1% | +11.2% | 40.1 | 1.8% |
|
MDT
Medtronic plc
|
$111.21B | -8.8% | +8.4% | 23.3 | 1.5% |
|
BSX
Boston Scientific Corp
|
$68.46B | -51.7% | +5.5% | 19.3 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BBNX | -7.5% | +0.5% | +15.6% | +2.0% | -47.5% |
| SPY | -0.4% | +1.4% | +6.3% | -1.0% | +8.4% |
| vs SPY | -7.1% | -0.9% | +9.3% | +3.1% | -55.9% |